These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27685612)

  • 1. Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine.
    Ikeda M; Sato A; Mochizuki N; Toyosaki K; Miyoshi C; Fujioka R; Mitsunaga S; Ohno I; Hashimoto Y; Takahashi H; Hasegawa H; Nomura S; Takahashi R; Yomoda S; Tsuchihara K; Kishino S; Esumi H
    Cancer Sci; 2016 Dec; 107(12):1818-1824. PubMed ID: 27685612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Change in plasma lactate concentration during arctigenin administration in a phase I clinical trial in patients with gemcitabine-refractory pancreatic cancer.
    Fujioka R; Mochizuki N; Ikeda M; Sato A; Nomura S; Owada S; Yomoda S; Tsuchihara K; Kishino S; Esumi H
    PLoS One; 2018; 13(6):e0198219. PubMed ID: 29856804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer.
    Löhr JM; Karimi M; Omazic B; Kartalis N; Verbeke CS; Berkenstam A; Frödin JE
    Pancreatology; 2016; 16(4):640-5. PubMed ID: 27234064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study.
    Karavasilis V; Samantas E; Koliou GA; Kalogera-Fountzila A; Pentheroudakis G; Varthalitis I; Linardou H; Rallis G; Skondra M; Papadopoulos G; Papatsibas G; Sgouros J; Goudopoulou A; Kalogeras KT; Dervenis C; Pectasides D; Fountzilas G
    Target Oncol; 2018 Dec; 13(6):715-724. PubMed ID: 30488350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
    Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
    J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
    Cascinu S; Gasparini G; Catalano V; Silva RR; Pancera G; Morabito A; Giordani P; Gattuso D; Catalano G
    Ann Oncol; 1999 Nov; 10(11):1377-9. PubMed ID: 10631469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1.
    Nakai Y; Isayama H; Ijichi H; Sasaki T; Kogure H; Yagioka H; Miyabayashi K; Mizuno S; Yamamoto K; Mouri D; Kawakubo K; Yamamoto N; Hirano K; Sasahira N; Tateishi K; Tada M; Koike K
    Cancer Sci; 2012 Aug; 103(8):1489-92. PubMed ID: 22515232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer.
    Zhen DB; Griffith KA; Ruch JM; Camphausen K; Savage JE; Kim EJ; Sahai V; Simeone DM; Zalupski MM
    Invest New Drugs; 2016 Dec; 34(6):733-739. PubMed ID: 27439894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
    Kessler ER; Eckhardt SG; Pitts TM; Bradshaw-Pierce EL; O'byrant CL; Messersmith WA; Nallapreddy S; Weekes C; Spratlin J; Lieu CH; Kane MA; Eppers S; Freas E; Leong S
    Invest New Drugs; 2016 Apr; 34(2):176-83. PubMed ID: 26715573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer.
    Ikeda M; Okada S; Tokuuye K; Ueno H; Okusaka T
    Br J Cancer; 2002 May; 86(10):1551-4. PubMed ID: 12085203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
    Morizane C; Okusaka T; Furuse J; Ishii H; Ueno H; Ikeda M; Nakachi K; Najima M; Ogura T; Suzuki E
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):313-9. PubMed ID: 18398614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.
    Nakamura K; Yamaguchi T; Ishihara T; Kobayashi A; Tadenuma H; Sudo K; Kato H; Saisho H
    Br J Cancer; 2005 Jun; 92(12):2134-9. PubMed ID: 15942632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.
    Mettu NB; Niedzwiecki D; Rushing C; Nixon AB; Jia J; Haley S; Honeycutt W; Hurwitz H; Bendell JC; Uronis H
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1025-1035. PubMed ID: 30895346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
    Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
    Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
    Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.
    Raftery L; Tepper JE; Goldberg RM; Blackstock AW; Aklilu M; Bernard SA; Ivanova A; Davies JM; O'Neil BH
    Am J Clin Oncol; 2013 Jun; 36(3):250-3. PubMed ID: 22547007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.
    Lowery MA; Yu KH; Kelsen DP; Harding JJ; Bomalaski JS; Glassman DC; Covington CM; Brenner R; Hollywood E; Barba A; Johnston A; Liu KC; Feng X; Capanu M; Abou-Alfa GK; O'Reilly EM
    Cancer; 2017 Dec; 123(23):4556-4565. PubMed ID: 28832976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer.
    Ikeda M; Takahashi H; Kondo S; Lahn MMF; Ogasawara K; Benhadji KA; Fujii H; Ueno H
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1169-1177. PubMed ID: 28451833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
    Ueno H; Okusaka T; Ikeda M; Ishiguro Y; Morizane C; Matsubara J; Furuse J; Ishii H; Nagase M; Nakachi K
    Oncology; 2005; 69(5):421-7. PubMed ID: 16319514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study.
    Maeda S; Motoi F; Onogawa T; Morikawa T; Shigeru O; Sakata N; Takadate T; Naitoh T; Rikiyama T; Katayose Y; Egawa S; Unno M
    Int J Clin Oncol; 2011 Oct; 16(5):539-45. PubMed ID: 21455624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.